HALO Stock Recent News

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Small biotech company Halozyme is behind some of the biggest names in medicine, including Johnson & Johnson's Darzalex and Roche's Tecentriq.

With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, with careful selection of industry leaders.

OCREVUS® subcutaneous (SC) injection offers a new 10-minute administration with comparable efficacy and safety to intravenous (IV) infusion Provides an additional treatment option without the need for IV facilities, expanding accessibility for patients SAN DIEGO , June 25, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of OCREVUS® (ocrelizumab) SC co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). OCREVUS® SC is a 10-minute injection that maintains the same twice-yearly schedule as the approved IV infusion.

VYVGART® Hytrulo  is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as a subcutaneous injection, approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) CIDP is the second FDA-approved indication for VYVGART® Hytrulo with ENHANZE® SAN DIEGO , June 21, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART® Hytrulo for CIDP is FDA-approved as a once weekly 30-to-90 second subcutaneous (SC) injection.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Halozyme (HALO) gains 13% as it raises its full-year 2024 financial guidance and updates its five-year financial outlook based on the new ENHANZE patent grant in Europe.

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?